EUVIMEDEUVIMED entdecken
Crossref

Fluoxetine Suppresses Osteosarcoma Progression In Vivo by Inducing Apoptosis and Inhibiting the AKT/mTOR/NF-κB Signaling Pathway

Yu-Hsi Chen, Chi-Huan Li, Shih-Wei Liu, Fei-Ting Hsu, Ming-Chou Ku

Anticancer Research · 2025

DOI: 10.21873/anticanres.17530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yu-Hsi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Osteosarcoma, Apoptosis, Fluoxetine. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Osteosarcoma (OSCC) remains a significant health concern, necessitating novel therapeutic strategies. This study investigated the anti-tumor effects of fluoxetine in an in vivo OSCC model. MATERIALS AND METHODS: Mice inoculated with U-2 OS cells were treated with fluoxetine (10 or 20 mg/kg) to evaluate tumor growth, metastasis, and underlying molecular mechanisms. RESULTS: Fluoxetine treatment resulted in a dose-dependent reduction in tumor volume and weight, without causing systemic toxicity, as confirmed by histopathological and biochemical analyses. Mechanistically, fluoxetine activated caspase-dependent apoptosis by up-regulating cleaved caspase-8, caspase-9, and caspase-3. It also inhibited OSCC metastasis by suppressing VEGF and MMP-9 expression, reducing epithelial-mesenchymal transition markers. Furthermore, fluoxetine significantly reduced the phosphorylation of AKT, PRAS40, mTOR, and NF-[Formula: see text]B, thereby disrupting key tumorigenic signaling pathways. CONCLUSION: Fluoxetine demonstrates promising anti-tumor activity in OSCC by inducing apoptosis, inhibiting metastasis, and targeting oncogenic signaling pathways. These findings suggest that fluoxetine may serve as a potential therapeutic agent for OSCC, warranting further investigation for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesOsteosarcomaApoptosisFluoxetineProto-Oncogene Proteins c-aktNF-kappa BBone NeoplasmsAnimalsSignal TransductionMiceCell Line, TumorHumansXenograft Model Antitumor AssaysCell ProliferationDisease ProgressionEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

AKT/PRAS40/mTOR/NF-BOsteosarcoma (OSCC)apoptosisfluoxetine

Substanzen

TOR Serine-Threonine KinasesFluoxetineProto-Oncogene Proteins c-aktNF-kappa BMTOR protein, human

Autor:innen und Institutionen

  • Department of Orthopedics, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
  • Department of Orthopedics, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
  • Department of Emergency Medicine, National Yang Ming Chiao Tung University Hospital, I-Lan, Taiwan, R.O.C.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C.
  • Department of Life Sciences, National Central University, Taoyuan, Taiwan, R.O.C.
  • Department of Orthopedics, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; showjoeku@gmail.com.

Zitieren

APA

Chen, Y. H., Li, C. H., Liu, S. W., Hsu, F. T., & Ku, M. C. (2025). Fluoxetine Suppresses Osteosarcoma Progression In Vivo by Inducing Apoptosis and Inhibiting the AKT/mTOR/NF-κB Signaling Pathway. Anticancer Research. https://doi.org/10.21873/anticanres.17530

Vancouver

Chen YH, Li CH, Liu SW, Hsu FT, Ku MC. Fluoxetine Suppresses Osteosarcoma Progression In Vivo by Inducing Apoptosis and Inhibiting the AKT/mTOR/NF-κB Signaling Pathway. Anticancer Research. 2025. doi:10.21873/anticanres.17530

BibTeX
@article{Chen2025,
  author = {Chen, Yu-Hsi and Li, Chi-Huan and Liu, Shih-Wei and Hsu, Fei-Ting and Ku, Ming-Chou},
  title = {Fluoxetine Suppresses Osteosarcoma Progression In Vivo by Inducing Apoptosis and Inhibiting the AKT/mTOR/NF-κB Signaling Pathway},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17530}
}
Kostenlos starten →